Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Effect of the rs2259816 polymorphism in the HNF1A gene on circulating levels of c-reactive protein and coronary artery disease (the ludwigshafen risk and cardiovascular health study)

  • Marcus E Kleber1,
  • Tanja B Grammer2,
  • Wilfried Renner3 and
  • Winfried März2, 4Email author
BMC Medical Genetics201011:157

https://doi.org/10.1186/1471-2350-11-157

Received: 11 May 2010

Accepted: 9 November 2010

Published: 9 November 2010

Abstract

Background

C-reactive protein is a well established marker of inflammation and has been used to predict future cardiovascular disease. It is still controversial if it plays an active role in the development of cardiovascular disease. Recently, polymorphisms in the gene for HNF1α have been linked to the levels of C-reactive protein and coronary artery disease.

Methods

We investigated the association of the rs2259816 polymorphism in the HNF1A gene with the circulating level of C-reactive protein and the hazard of coronary artery disease in the LURIC Study cohort.

Results

Compared to CC homozygotes, the level of C-reactive protein was decreased in carriers of at least one A-allele. Each A-allele decreased CRP by approximately 15%. The odds ratio for coronary artery disease was only very slightly increased in carriers of the A-allele and this association did not reach statistical significance.

Conclusions

In the LURIC Study cohort the A-allele of rs2259816 is associated with decreased CRP but not with coronary artery disease.

Background

C-reactive protein (CRP) is a well established biochemical marker of inflammation and has been used to predict future cardiovascular disease [13]. As its level is increased in patients suffering from coronary artery disease (CAD) the idea has been put forward that it might play an active role in the development of the disease. Although numerous studies have been conducted, this issue has not been finally settled yet [46]. Most of these studies didn't find an association between CRP and CAD [713] whereas a few did present some evidence in favor of this idea [1416].

A recent meta-analysis has shown that associations of CRP with ischemic vascular disease depend considerably on conventional risk factors and other markers of inflammation making a causal role of CRP in the development of CAD also unlikely [17].

Genetic factors have been estimated to have a great influence on the variance in plasma CRP level [1820]. A number of polymorphisms of the CRP gene (MIM 123260) or its promoter that act in this way have been described so far [811, 1416, 2132] but they only account for a minor part of the assumed heritability.

Recently, polymorphisms in the HNF1A gene (also known asTCF1, MIM 142410) have been linked to the levels of C-reactive protein and coronary artery disease [3336]. This gene encodes the transcription factor hepatocyte nuclear factor (HNF)-1α which regulates the transcription of numerous genes in miscellaneous tissues, including genes that are expressed exclusively in the liver [3740]. The CRP gene promoter contains a HNF-1α binding site which is involved in the regulation of basal and constitutive CRP synthesis in the liver [41].

In our study we attempted to confirm the reported association of rs2259816 to CRP and CAD in the LURIC Study cohort.

Methods

Study design and participants

The Ludwigshafen Risk and Cardiovascular Health (LURIC) study includes consecutive white patients hospitalized for coronary angiography between June 1997 and May 2001. A detailed description of LURIC has been published [42]. The study was approved by the ethics review committee at the "Landesärztekammer Rheinland-Pfalz" (Mainz, Germany). Written informed consent was obtained from each of the participants. Clinical indications for angiography were chest pain or non-invasive tests consistent with myocardial ischemia. To limit clinical heterogeneity, individuals suffering from acute illness other than acute coronary syndromes, chronic non-cardiac diseases and a history of malignancy within the five past years were excluded.

CAD has been defined angiographically using the maximum luminal narrowing estimated by visual analysis. CAD was defined as the presence of a visible luminal narrowing (> 20% stenosis) in at least one of 15 coronary segments according to a classification of the American Heart Association [43]. Individuals with stenosis < 20% were considered as not having CAD. To examine the impact of other definitions of CAD on the current analysis, we provisionally used the presence of one stenosis > 50% (n = 2158) as a criterion. MI was defined as evidence for any MI (acute, previous, ST elevation MI, STEMI, or non ST elevation MI, NSTEMI). Acute MI was defined as a MI that had occurred within the four weeks prior to enrolment into LURIC. A previous MI was diagnosed if a MI had been survived for more than one month before enrolment into LURIC. A definite STEMI was diagnosed if typical ECG changes were present along with prolonged chest pain refractory to sublingual nitrates and/or enzyme or troponin T elevations. NSTEMI was diagnosed if symptoms and/or enzyme criteria, but not the ECG criteria for STEMI were met. Previous MI was also graded as definite if a hospitalisation with a discharge diagnosis of MI was documented.

Among the 3113 individuals in whom rs2259816 genotypes were available, 665 (21.4%) had no angiographic CAD while 2448 (78.6%) had CAD.

Diabetes mellitus was diagnosed according to the criteria of the American Diabetes Association [44]. Further, individuals with a history of diabetes or treatment with oral antidiabetics or insulin were considered diabetic. Hypertension was defined as a systolic and/or diastolic blood pressure ≥ 140 and/or ≥ 90 mm Hg or a significant history of hypertension.

Laboratory Procedures

Fasting blood samples were obtained by venipuncture in the early morning. 'Sensitive' C-reactive protein was measured by immunonephelometry on a Behring Nephelometer II (N High Sensitivity CRP, Dade Behring, Marburg, Germany) after completion of the patient recruitment in 2001 in samples stored at -80°C. In the C-reactive protein assay used, the limit of detection for C-reactive protein is 0.17 mg/L; it is linear up to 500 mg/L. The lowest and the highest C-reactive protein concentrations encountered in this study were 0.17 and 269 mg/L, respectively. Blood glucose was determined enzymatically using the hexokinase/glucose-6-phosphate dehydrogenase method (Roche Diagnostics, Mannheim, Germany). Lipoproteins were separated by a combined ultracentrifugation-precipitation method (β-quantification) [42]. Cholesterol and triglycerides were measured with enzymatic reagents from WAKO (Neuss, Germany) on a WAKO R30 or Olympus AU640 analyser [42].

Analysis of the rs2259816 genotype

Genomic DNA was prepared from EDTA anticoagulated peripheral blood by using a common salting-out procedure. The C/A polymorphism rs2259816 was genotyped by a 5' exonuclease assay (Taqman®). Primer and probe sets were designed and manufactured using Applied Biosystem's 'Assay-by-Design' custom service.

Statistics

Continuous variables were first tested for normality and then compared between groups by univariate analysis of variance (ANOVA). CRP was not normally distributed and had to be logarithmically transformed before performing ANOVA. Co-variables were used as indicated.

In models assuming a co-dominant (additive) effect of the alleles, genotypes were coded as 0, 1, and 2, respectively, and genotypes were either treated as interval-scaled or categorical variables, the most frequent genotype being considered as the reference category in the latter case. When assuming a dominant effect, the genotype CC was coded as 0, and the combined remaining ones were coded as 1. When assuming a recessive effect, the genotypes CC and AC were coded as 0, genotype AA as 1. Further, the estimated marginal means of the dependent variables along with their 95% confident intervals (CI) are reported in the ANOVA procedures and the least significant difference t-test was used for post hoc comparisons. Estimated marginal means are not observed means; rather they represent predicted means estimated at the co-variables held at their respective actual means. Finally, we analyzed the association between rs2259816 genotypes and angiographic CAD in an analogous fashion by logistic regression. Multivariable adjustment was carried out in two steps, first for sex and age, and then, in addition, for cardiovascular risk factors (body mass index, diabetes mellitus, hypertension, smoking, LDL-C, HDL-C and TG. All statistical tests were two-sided. P < 0.05 was considered statistically significant. The SPSS 16.0 statistical package (SPSS Inc., Chicago, IL, USA) was used.

Results

Study participants

We included 3113 subjects in the current analysis. Compared to the control group without CAD, patients with angiographic CAD were significantly older; current or past smoking, diabetes mellitus, and hypertension were more prevalent. CAD patients had higher systolic blood pressure, higher fasting glucose, higher triglycerides and lower HDL-C. Crude LDL-C concentrations were higher in controls, due to the fact that 57.1% of CAD patients were treated with lipid-lowering drugs compared to 18.3% of controls. When we accounted for the use of lipid-lowering drugs, age, and gender, however, LDL-C was significantly higher in CAD patients (adjusted mean 118 mg/dl) than in controls (adjusted mean 113 mg/dl). Body mass index and diastolic blood pressure were similar between patients and controls (Table 1).
Table 1

Baseline characteristics and risk factors in patients with angiographically proven CAD as compared to controls without CAD.

 

No CAD

CAD

P 1

 

(n = 665)

(n = 2448)

 

Age (years) means ± SD

58 ± 12

64 ± 10

< 0.001

Body mass index (kg/m2) means ± SD

27 ± 4

28 ± 4

n.s.

Smoker (former and current)

324 (49%)

1675 (68%)

 

Diabetes mellitus

125 (19%)

872 (36%)

 

Systemic Hypertension

417 (63%)

1841 (75%)

 

Systolic blood pressure (mm Hg) means ± SD

136 ± 22

142 ± 24

0.0143

Diastolic blood pressure (mm Hg) means ± SD

80 ± 11

81 ± 11

n.s.

Fasting blood glucose (mg/dl) means ± SD

105 ± 28

116 ± 37

< 0.001

LDL-C(mg/dl) means ± SD

120 ± 31

116 ± 35

0.0014

HDL-C (mg/dl) means ± SD

43 ± 12

38 ± 10

< 0.0014

Triglycerides (mg/dl)median (25th and 75th percentile)

132

(97-194)

150

(113-202)

< 0.001

1Analysis of variance or logistic regression, respectively, adjusted for age and gender.2Analysis of variance adjusted for gender only.3Analysis of variance additionally adjusted for use of lipid-lowering drugs, beta blockers, ACE inhibitors, AT1 receptor antagonists, calcium channel blockers and diuretics.

4Analysis of variance additionally adjusted for use of lipid-lowering drugs.

Association of rs2259816 with CRP

To analyze the association of levels of CRP with rs2259816 genotype, we used analysis of variance in which the genotype groups (defined by the presence or the absence of an A-allele) were included as main effects; statistical adjustments were made for age, sex and cardiovascular risk factors, namely body mass index, diabetes mellitus, hypertension, smoking, LDL-C, HDL-C and TG (Figure 1).
Figure 1

Levels of CRP according to rs2259816 genotype. CRP by rs2259816 genotype. Displayed are the estimated marginal means (± 95% confidence intervals) of a linear model (ANOVA) adjusted for age, gender, smoking (never, former, current), body mass index, diabetes mellitus, hypertension, LDL-C, HDL-C and TG. The A-allele of rs2259816 was associated with significantly lower CRP (P <0.001)

Compared to CC homozygotes, carriers of the A-allele had significantly lower plasma concentration of CRP (P < 0.001). The circulating plasma concentration decreased from 3.88 mg/l (3.63 - 4.16) in CC homozygotes to 3.43 mg/l (3.21 - 3.65) in heterozygotes and to 2.95 mg/l (2.64 - 3.31) in AA homozygotes. As statins also lower CRP we repeated our analysis including only patients not receiving lipid lowering therapy but this yielded basically the same results (data not shown).

rs2259816 and coronary artery disease

Compared to CC homozygotes, the prevalence of CAD was basically the same in CA heterozygotes with OR ranging from 1.005 to 1.038, depending on the statistical model (Table 2). Even for AA homozygotes there was only a slightly higher increase with OR ranging from 1.050 to 1.083. Both associations were not statistically significant. There was no significant association between rs2259816 and CAD in any of the tested models either.
Table 2

Odds ratios (OR) for angiographic CAD according to the rs2259816 genotype.

rs2259816 genotype

Model 1 OR (95% CI)

P

Model 2 OR (95% CI)

P

Model 3 OR (95% CI)

P

CC (n = 1264)

1.0reference

 

1.0reference

 

1.0reference

 

CA1 (n = 1395)

1.005 (0.835 - 1.210)

0.957

1.013 (0.832 - 1.232)

0.900

1.038 (0.847 - 1.272)

0.717

AA1 (n = 454)

1.050 (0.807 - 1.367)

0.716

1.045 (0.792 - 1.380)

0.755

1.083 (0.811 - 1.445)

0.590

CC vs CA vs AA

1.020 (0.901 - 1.154)

0.755

1.020 (0.895 - 1.162)

0.766

1.040 (0.908 - 1.191)

0.572

CC vs CA + AA

1.016 (0.835 - 1.209)

0.860

1.021 (0.848 - 1.227)

0.829

1.049 (0.866 - 1.270)

0.626

CC + CA vs AA

1.047 (0.820 - 1.338)

0.712

1.038 (0.802 - 1.344)

0.775

1.061 (0.812 - 1.387)

0.664

1Genotypes treated as categorical variables and compared to the reference category.

Model 1: unadjusted.

Model 2: adjusted for age, and gender.

Model 3: in addition adjusted for type 2 diabetes, body mass index, smoking, hypertension, LDL-C, HDL-C, TG

We further looked for an association of rs2259816 with the friesinger score, a quantitative measure of the severity of CAD. ANOVA analysis didn't show a significant difference between the three genotype groups (Figure 2).
Figure 2

Friesinger score according to rs2259816 genotype. Friesinger score by rs2259816 genotype. Displayed are the estimated marginal means (± 95% confidence intervals) of a linear model (ANOVA) adjusted for age, gender, smoking (never, former, current), body mass index, diabetes mellitus, hypertension, LDL-C, HDL-C and TG.

Discussion

Recently, the discovery that the reduction of CRP levels in individuals who are not considered to be at high risk for cardiovascular disease by National Cholesterol Education Program guidelines significantly decreased the rate of first major cardiovascular events as well as total mortality has renewed the interest in CRP as possible biomarker for deciding whether an individual should receive treatment [45, 46]. The JUPITER trial showed the benefit of statin treatment even for individuals with high CRP but normal LDL-C [45, 47].

As a large part of the variability of plasma CRP levels is due to genetic causes attempts have been made to identify the responsible genes.

Besides polymorphisms in the CRP gene itself other genes have been identified, one of them being the gene for transcription factor hepatocyte nuclear factor (HNF)-1α. Several polymorphisms in this gene have been linked to lower CRP [33, 34]. We analyzed one of these polymorphisms, rs2259816, in the LURIC cohort. In LURIC CRP is increased in CAD patients compared to healthy controls but the increase is only significant for patients with acute coronary syndromes, not for patients with stable CAD [48]. For the rs2259816 polymorphism we found a highly significant association with circulating levels of CRP confirming other reports. Individuals homozygous for the rare A allele showed an approximately 25% lower CRP compared to individuals homozygous for the C allele. However, this SNP had no impact on the risk of CAD in LURIC. The odds ratio even increased marginally for heterozygous or homozygous carriers of the A allele compared to CC homozygotes but this increase did not reach statistical significance. On the other hand our study has only a limited power to detect small effects on the risk of CAD. The estimated marginal mean of CRP in CC homozygotes was 3.88 mg/L compared to 2.95 mg/L in AA homozygotes. According to König et al. [49], who described a log-linear relationship between CRP and CAD, this difference should translate into an OR for CAD of only 1.13. To increase our power we looked for an association of rs2259816 with the friesinger index which is a quantitative score of the severity of CAD. Although there is also a slight increase in friesinger score for carriers of the A allele this difference was not significant, strengthening the notion that there is no causal relationship between CRP and CAD.

These findings are in line with Grammer et al. who didn't find an association of polymorphisms in the CRP gene itself and CAD in LURIC [12] and support the view that CRP does not play a causal role in the development of CAD.

Nevertheless, we think that HNF-1α might play an important role as a link between metabolic and inflammatory pathways. As such it could be involved in the pathogenesis of atherosclerosis and further work is required to define the role of HNF-1α more exactly.

Conclusions

In the LURIC Study cohort the A-allele of the rs2259816 polymorphism in the HNF1A gene is associated with decreased CRP but not with coronary artery disease. These results support the view that CRP does not play an active role in the development of CAD.

Declarations

Acknowledgements

The authors extend appreciation to the participants of the LURIC study without their collaboration this article would not have been written. We thank the LURIC study team either temporarily or permanently involved in patient recruitment, sample and data handling, and the laboratory staff at the Ludwigshafen General Hospital and the Universities of Freiburg and Ulm, Germany.

The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 201668; AtheroRemo.

Authors’ Affiliations

(1)
LURIC Study nonprofit LLC
(2)
Synlab Centre of Laboratory Diagnostics
(3)
Clinical Institute of Medical and Chemical Laboratory Diagnostics, Medical University of Graz
(4)
Institute of Public Health, Social and Preventive Medicine, Medical Faculty of Mannheim, University of Heidelberg

References

  1. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB: Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000, 321 (7255): 199-204. 10.1136/bmj.321.7255.199.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Ridker PM, Bassuk SS, Toth PP: C-reactive protein and risk of cardiovascular disease: evidence and clinical application. Curr Atheroscler Rep. 2003, 5 (5): 341-349. 10.1007/s11883-003-0004-3.View ArticlePubMedGoogle Scholar
  3. Ridker PM: Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003, 107 (3): 363-369. 10.1161/01.CIR.0000053730.47739.3C.View ArticlePubMedGoogle Scholar
  4. Hingorani AD, Shah T, Casas JP, Humphries SE, Talmud PJ: C-reactive protein and coronary heart disease: predictive test or therapeutic target?. Clin Chem. 2009, 55 (2): 239-255. 10.1373/clinchem.2008.115923.View ArticlePubMedGoogle Scholar
  5. Schunkert H, Samani NJ: Elevated C-reactive protein in atherosclerosis--chicken or egg?. N Engl J Med. 2008, 359 (18): 1953-1955. 10.1056/NEJMe0807235.View ArticlePubMedGoogle Scholar
  6. Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB: C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008, 264 (4): 295-314. 10.1111/j.1365-2796.2008.02015.x.View ArticlePubMedGoogle Scholar
  7. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, Gaffney D, Packard CJ, O'Reilly DS, Juhan-Vague I, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Kooistra T, Stephens JW, Hurel SJ, Livingstone S, Colhoun HM, Miller GJ, Bautista LE, Meade T, Sattar N, Humphries SE, Hingorani AD: Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol. 2006, 35 (4): 922-931. 10.1093/ije/dyl041.View ArticlePubMedGoogle Scholar
  8. Zee RY, Ridker PM: Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis. 2002, 162 (1): 217-219. 10.1016/S0021-9150(01)00703-1.View ArticlePubMedGoogle Scholar
  9. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R, Cook NR, Ridker PM, Kwiatkowski DJ: Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet. 2005, 69 (Pt 6): 623-638. 10.1111/j.1529-8817.2005.00210.x.View ArticlePubMedGoogle Scholar
  10. Kardys I, de Maat MP, Uitterlinden AG, Hofman A, Witteman JC: C-reactive protein gene haplotypes and risk of coronary heart disease: the Rotterdam Study. Eur Heart J. 2006, 27 (11): 1331-1337. 10.1093/eurheartj/ehl018.View ArticlePubMedGoogle Scholar
  11. Zhang L, Kao WH, Berthier-Schaad Y, Plantinga L, Fink N, Smith MW, Coresh J: C-Reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. Am J Kidney Dis. 2007, 49 (1): 118-126. 10.1053/j.ajkd.2006.10.008.View ArticlePubMedGoogle Scholar
  12. Grammer TB, Marz W, Renner W, Bohm BO, Hoffmann MM: C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study. Eur Heart J. 2009, 30 (2): 170-182. 10.1093/eurheartj/ehn191.View ArticlePubMedGoogle Scholar
  13. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG: Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008, 359 (18): 1897-1908. 10.1056/NEJMoa0707402.View ArticlePubMedGoogle Scholar
  14. Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C, Wong M, Witrak L, Rieder MJ, Nickerson DA: Genetic variation is associated with C-reactive protein levels in the Third National Health and Nutrition Examination Survey. Circulation. 2006, 114 (23): 2458-2465. 10.1161/CIRCULATIONAHA.106.615740.View ArticlePubMedGoogle Scholar
  15. Lange LA, Carlson CS, Hindorff LA, Lange EM, Walston J, Durda JP, Cushman M, Bis JC, Zeng D, Lin D, Kuller LH, Nickerson DA, Psaty BM, Tracy RP, Reiner AP: Association of polymorphisms in the CRP gene with circulating C-reactive protein levels and cardiovascular events. JAMA. 2006, 296 (22): 2703-2711. 10.1001/jama.296.22.2703.View ArticlePubMedGoogle Scholar
  16. Jylhava J, Eklund C, Pessi T, Raitakari OT, Juonala M, Kahonen M, Viikari JS, Lehtimaki T, Hurme M: Genetics of C-reactive protein and complement factor H have an epistatic effect on carotid artery compliance: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol. 2009, 155 (1): 53-58. 10.1111/j.1365-2249.2008.03752.x.View ArticlePubMedPubMed CentralGoogle Scholar
  17. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, Danesh J: C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 375 (9709): 132-140.Google Scholar
  18. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, Tracy RP: Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis. 2001, 154 (3): 681-689. 10.1016/S0021-9150(00)00586-4.View ArticlePubMedGoogle Scholar
  19. Retterstol L, Eikvar L, Berg K: A twin study of C-Reactive Protein compared to other risk factors for coronary heart disease. Atherosclerosis. 2003, 169 (2): 279-282. 10.1016/S0021-9150(03)00192-8.View ArticlePubMedGoogle Scholar
  20. MacGregor AJ, Gallimore JR, Spector TD, Pepys MB: Genetic effects on baseline values of C-reactive protein and serum amyloid a protein: a comparison of monozygotic and dizygotic twins. Clin Chem. 2004, 50 (1): 130-134. 10.1373/clinchem.2003.028258.View ArticlePubMedGoogle Scholar
  21. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP: Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun. 2002, 3 (1): 14-19. 10.1038/sj.gene.6363820.View ArticlePubMedGoogle Scholar
  22. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, Sharma P, Lowe GD, World MJ, Humphries SE, Hingorani AD: Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol. 2003, 23 (11): 2063-2069. 10.1161/01.ATV.0000084640.21712.9C.View ArticlePubMedGoogle Scholar
  23. Wolford JK, Gruber JD, Ossowski VM, Vozarova B, Antonio Tataranni P, Bogardus C, Hanson RL: A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab. 2003, 78 (2): 136-144. 10.1016/S1096-7192(02)00230-5.View ArticlePubMedGoogle Scholar
  24. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, Powell RJ, Isenberg DA, Walport MJ, Vyse TJ: Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet. 2004, 13 (1): 137-147. 10.1093/hmg/ddh021.View ArticlePubMedGoogle Scholar
  25. Obisesan TO, Leeuwenburgh C, Phillips T, Ferrell RE, Phares DA, Prior SJ, Hagberg JM: C-reactive protein genotypes affect baseline, but not exercise training-induced changes, in C-reactive protein levels. Arterioscler Thromb Vasc Biol. 2004, 24 (10): 1874-1879. 10.1161/01.ATV.0000140060.13203.22.View ArticlePubMedPubMed CentralGoogle Scholar
  26. de Maat MP, Bladbjerg EM, Hjelmborg JB, Bathum L, Jespersen J, Christensen K: Genetic influence on inflammation variables in the elderly. Arterioscler Thromb Vasc Biol. 2004, 24 (11): 2168-2173. 10.1161/01.ATV.0000143856.01669.e7.View ArticlePubMedGoogle Scholar
  27. Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, Boquist S, Ericsson CG, Watkins H, Hamsten A, Tornvall P: A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein. Atherosclerosis. 2005, 178 (1): 193-198. 10.1016/j.atherosclerosis.2004.08.018.View ArticlePubMedGoogle Scholar
  28. Suk HJ, Ridker PM, Cook NR, Zee RY: Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis. 2005, 178 (1): 139-145. 10.1016/j.atherosclerosis.2004.07.033.View ArticlePubMedGoogle Scholar
  29. Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A, Zakharkin SO, George V, Allison DB, Cooper GS, Xie F, Fan Z, Edberg JC, Kimberly RP: Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level. J Mol Med. 2005, 83 (6): 440-447. 10.1007/s00109-005-0658-0.View ArticlePubMedGoogle Scholar
  30. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, Liu K, Williams OD, Iribarren C, Lewis EC, Fornage M, Boerwinkle E, Gross M, Jaquish C, Nickerson DA, Myers RM, Siscovick DS, Reiner AP: Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet. 2005, 77 (1): 64-77. 10.1086/431366.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney JF, Wilson PW, Newton-Cheh C, Musone SL, Camargo AL, Drake JA, Levy D, O'Donnell CJ, Hirschhorn JN, Benjamin EJ: Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation. 2006, 113 (11): 1415-1423. 10.1161/CIRCULATIONAHA.105.591271.View ArticlePubMedGoogle Scholar
  32. Eklund C, Kivimaki M, Islam MS, Juonala M, Kahonen M, Marniemi J, Lehtimaki T, Viikari J, Raitakari OT, Hurme M: C-reactive protein genetics is associated with carotid artery compliance in men in The Cardiovascular Risk in Young Finns Study. Atherosclerosis. 2008, 196 (2): 841-848. 10.1016/j.atherosclerosis.2007.01.027.View ArticlePubMedGoogle Scholar
  33. Reiner AP, Barber MJ, Guan Y, Ridker PM, Lange LA, Chasman DI, Walston JD, Cooper GM, Jenny NS, Rieder MJ, Durda JP, Smith JD, Novembre J, Tracy RP, Rotter JI, Stephens M, Nickerson DA, Krauss RM: Polymorphisms of the HNF1A gene encoding hepatocyte nuclear factor-1 alpha are associated with C-reactive protein. Am J Hum Genet. 2008, 82 (5): 1193-1201. 10.1016/j.ajhg.2008.03.017.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Ridker PM, Pare G, Parker A, Zee RY, Danik JS, Buring JE, Kwiatkowski D, Cook NR, Miletich JP, Chasman DI: Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study. Am J Hum Genet. 2008, 82 (5): 1185-1192. 10.1016/j.ajhg.2008.03.015.View ArticlePubMedPubMed CentralGoogle Scholar
  35. Erdmann J, Grosshennig A, Braund PS, Konig IR, Hengstenberg C, Hall AS, Linsel-Nitschke P, Kathiresan S, Wright B, Tregouet DA, Cambien F, Bruse P, Aherrahrou Z, Wagner AK, Stark K, Schwartz SM, Salomaa V, Elosua R, Melander O, Voight BF, O'Donnell CJ, Peltonen L, Siscovick DS, Altshuler D, Merlini PA, Peyvandi F, Bernardinelli L, Ardissino D, Schillert A, Blankenberg S, et al: New susceptibility locus for coronary artery disease on chromosome 3q22.3. Nat Genet. 2009Google Scholar
  36. Armendariz AD, Krauss RM: Hepatic nuclear factor 1-alpha: inflammation, genetics, and atherosclerosis. Curr Opin Lipidol. 2009, 20 (2): 106-111. 10.1097/MOL.0b013e3283295ee9.View ArticlePubMedGoogle Scholar
  37. Courtois G, Morgan JG, Campbell LA, Fourel G, Crabtree GR: Interaction of a liver-specific nuclear factor with the fibrinogen and alpha 1-antitrypsin promoters. Science. 1987, 238 (4827): 688-692. 10.1126/science.3499668.View ArticlePubMedGoogle Scholar
  38. Bell GI, Polonsky KS: Diabetes mellitus and genetically programmed defects in beta-cell function. Nature. 2001, 414 (6865): 788-791. 10.1038/414788a.View ArticlePubMedGoogle Scholar
  39. Koudritsky M, Domany E: Positional distribution of human transcription factor binding sites. Nucleic Acids Res. 2008, 36 (21): 6795-6805. 10.1093/nar/gkn752.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Odom DT, Dowell RD, Jacobsen ES, Nekludova L, Rolfe PA, Danford TW, Gifford DK, Fraenkel E, Bell GI, Young RA: Core transcriptional regulatory circuitry in human hepatocytes. Mol Syst Biol. 2006, 2: 2006 0017-10.1038/msb4100059.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Li SP, Goldman ND: Regulation of human C-reactive protein gene expression by two synergistic IL-6 responsive elements. Biochemistry. 1996, 35 (28): 9060-9068. 10.1021/bi953033d.View ArticlePubMedGoogle Scholar
  42. Winkelmann BR, Marz W, Boehm BO, Zotz R, Hager J, Hellstern P, Senges J: Rationale and design of the LURIC study--a resource for functional genomics, pharmacogenomics and long-term prognosis of cardiovascular disease. Pharmacogenomics. 2001, 2 (1 Suppl 1): S1-73. 10.1517/14622416.2.1.S1.View ArticlePubMedGoogle Scholar
  43. Austen WG, Edwards JE, Frye RL, Gensini GG, Gott VL, Griffith LS, McGoon DC, Murphy ML, Roe BB: A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association. Circulation. 1975, 51 (4 Suppl): 5-40.View ArticlePubMedGoogle Scholar
  44. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006, 29 (Suppl 1): S43-48.Google Scholar
  45. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009, 373 (9670): 1175-1182. 10.1016/S0140-6736(09)60447-5.View ArticlePubMedGoogle Scholar
  46. Koenig W: Is hsCRP Back on Board? Implications from the JUPITER Trial. Clin Chem. 2009, 55 (2): 216-218. 10.1373/clinchem.2008.115915.View ArticlePubMedGoogle Scholar
  47. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008, 359 (21): 2195-2207. 10.1056/NEJMoa0807646.View ArticlePubMedGoogle Scholar
  48. Marz W, Winkler K, Nauck M, Bohm BO, Winkelmann BR: Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). Am J Cardiol. 2003, 92 (3): 305-308. 10.1016/S0002-9149(03)00633-7.View ArticlePubMedGoogle Scholar
  49. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, Hutchinson WL, Pepys MB: C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999, 99 (2): 237-242.View ArticlePubMedGoogle Scholar
  50. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2350/11/157/prepub

Copyright

© Kleber et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement